Richmond, VANCT06636123Now EnrollingIRB Ready

Castration-resistant Prostate Cancer Clinical Trial in Richmond, VA

Access cutting-edge castration-resistant prostate cancer treatment through this clinical trial at a research site in Richmond. Study-provided care at no cost to qualified participants.

Sponsored by Virginia Commonwealth University

Quick Self-Assessment

See if you qualify for this Richmond location

Preparing your pre-screening questions…

Expert Care in Richmond

Access castration-resistant prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related castration-resistant prostate cancer treatment provided free

Apply for This Richmond Location

Check if you qualify for this castration-resistant prostate cancer clinical trial in Richmond, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Richmond

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Richmond site if eligible
  4. 4Begin participation

About This Castration-resistant Prostate Cancer Study in Richmond

The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.

Sponsor: Virginia Commonwealth University

Who Can Participate

Inclusion Criteria

Patients diagnosed with prostate cancer and treated with androgen deprivation therapy (ADT) and at least one androgen receptor pathway inhibitor (ARPI) (eg, abiraterone, enzalutamide, apalutamide or darolutamide). Previous prostate-specific membrane antigen (PSMA)-targeted therapy or cytotoxic chemotherapy is allowed but not required.
Androgen levels ≤50 ng/dL (≤1.73 nmol/L).
Disease progression following ADT and ARPI treatment described
PSA progression over 2 assessments, defined as rising PSA values from 2 consecutive assessments with an interval of at least 7 days between assessments. PSA levels prior to study enrollment are considered and appropriate for inclusion.
Measurable disease by RECIST v1.1 on chest/abdomen/pelvis CT or evaluable disease observed on bone scan.
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
Appropriate hepatic function defined by a total bilirubin (TBL) ≤1.5 × the upper limit of normal (ULN), alanine aminotransferase (ALT) AND aspartate aminotransferase (AST) ≤3 × ULN at screening.
Appropriate kidney function defined by calculated or actual creatinine clearance ≥30 mL/min
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3.
Platelets ≥100,000 cells/mm3.
Serum hemoglobin level ≥8 g/dL.
Agree to not donate blood or sperm during the study and for 90 days after the last dose of study treatment.
Patients with sexual partners of childbearing potential must agree to use highly effective methods of contraception throughout the study
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Any investigational agent: within 4 weeks OR within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, before initiating study treatment.
Low PSA (≤10 ng/mL) at initial presentation (before ADT or at symptomatic progression in the castrate setting) plus high volume (≥20) bone metastases.
Simultaneous enrollment in any other cancer treatment interventional clinical trial.
Active, uncontrolled diarrhea leading to dehydration or electrolyte disturbances not controlled with oral repletion.
Grade ≥3 uncontrolled infection.
Major surgery (in the opinion of the treating investigator) ≤3 weeks before initiating study treatment.
Not having fully recovered to a grade of 1 or lower from any surgery-related adverse effects within the 3 weeks preceding the start of the study treatment.
Small cell, anaplastic, or neuroendocrine component.
Known active brain metastasis.
Known active leptomeningeal disease.
Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the medications included in the study treatment must be discontinued ≥2 weeks prior to initiating study treatment unless otherwise noted:
Monoamine oxidase inhibitors (MAOI) use; must discontinue use 10 days prior to initiating study therapy.
Strong or moderate CYP1A2, CYP3A4 and CYP2C19 inhibitors.
Rucaparib, Olaparib and Talazoparib, due to their common findings of liver enzyme elevation.
Inability to swallow medication.
Known hypersensitivity to GZ17-6.02 components (curcumin, harmine, and isovanillin) or excipients.
Known or suspected malabsorption condition or obstruction.
Active untreated hepatitis B or C" and "Known liver cirrhosis of any cause, active nonalcoholic steatohepatitis, or nonalcoholic fatty liver disease. Note: no additional testing necessary to confirm
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Richmond?

Yes, this clinical trial (NCT06636123) has an active research site in Richmond, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Castration-resistant Prostate Cancer Treatment Options in Richmond, VA

If you're searching for castration-resistant prostate cancer treatment options in Richmond, VA, this clinical trial (NCT06636123) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Richmond research site is actively enrolling participants for this clinical trial. You'll receive care from experienced castration-resistant prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all castration-resistant prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Richmond, VA

See all prostate cancer clinical trials recruiting in Richmond — not just this study.

Browse Prostate Cancer Trials in Richmond →

Browse More Trials by Condition

Prostate Cancer TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Richmond?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Richmond, VA